Bristol-Myers Squibb Company announced that the FDA has accepted, for filing and review, the Biologics License Application for ipilimumab for the treatment of adult patients with advanced melanoma who have been previously treated.
Johnson & Johnson is creating a new position to oversee companywide quality, manufacturing and compliance issues and appointing chief quality officers for each of its three major business units.
StemCells, Inc., announced the publication of new preclinical data demonstrating that the company’s proprietary human neural stem cells restore lost motor function in mice with chronic spinal cord injury.
Shares of Endo Pharmaceuticals Holdings Inc. jumped this week after an analyst said Endo can keep generic versions of its painkiller Opana ER from being approved, which would sustain sales until Endo starts selling a new version.
One of the prerequisites for the success of a clinical trial is to ensure that the effective drugs and placebos involved cannot be distinguished from each other. Schreiner MediPharm has now developed a solution which neutralizes the appearance of liquids in transparent containers.
Bio-Rad Laboratories introduces the SsoFast EvaGreen control assay, a prepackaged kit that helps labs conveniently verify their real-time PCR instrument performance.
Genetix announces that it was granted a patent, US 7,776,584. Aspects of this patent are incorporated into ClonePix FL, which is used for the screening and selection of cell lines producing biopharmaceuticals.
Phylogica Ltd, a public Australian drug discovery company, announced that they have entered into an agreement with MedImmune to evaluate Phylogica’s proprietary Phylomer peptide library for novel antimicrobial peptides.
Shares of Jazz Pharmaceuticals Inc. jumped after federal health officials said one of its drugs appears effective for treating a chronic pain disorder.
A special set of sugars found on some disease-causing pathogens helps those pathogens fight the body's natural defenses as well as vaccines, say two Iowa State University researchers.
A team of scientists published results of a study that suggests new ways in which tumor cells develop resistance to one of the most successful targeted therapies, the small-molecule drug Tarceva.
Tanner Pharmaceuticals Inc. announced that it has entered into an exclusive agreement with the Chao Center for the rights to distribute cycloserine, a drug to treat multidrug-resistant tuberculosis, in the Latin American market.
XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced that it has sold its royalty interest in CIMZIA marketed by UCB S.A. for $4 million to an undisclosed buyer.
Xenon Pharmaceuticals Inc. announced that it has initiated a phase 2 clinical trial evaluating its novel topical XEN402 therapy for the treatment of postherpetic neuralgia.
Abbott announced that the U.S. Food and Drug Administration approved the supplemental New Drug Application for CREON Delayed-Release Capsules that now includes dosing guidance specific to patients with exocrine pancreatic insufficiency.